Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 5:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: c-kit+ cells Clear all
Terminated Phase 2 Interventional

Optimization for Regorafenib in HCC

NCT04476329
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Regorafenib 40 MG
Drug
Lead sponsor
SC Liver Research Consortium, LLC
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
9
States / cities
Gilbert, Arizona • Long Beach, California • New Orleans, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Sep 5, 2026, 5:42 PM EDT
Completed Phase 2 Interventional Results available

Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT01806571
View directory record Official record
Conditions
Untreated Adult Acute Myeloid Leukemia
Interventions
Cytarabine, Daunorubicin Hydrochloride, Laboratory Biomarker Analysis, Nilotinib, Pharmacological Study
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 69 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 30, 2023 · Synced Sep 5, 2026, 5:42 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Intrathecal Amniotic Fluid Stem Cells for Progressive Multiple Sclerosis

NCT06841068
View directory record Official record
Conditions
Multiple Sclerosis, Progressive
Interventions
Amniotic fluid or placental CD117 stem cells
Biological
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 5, 2026, 5:42 PM EDT
Terminated Phase 2 Interventional Results available

AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer

NCT00427973
View directory record Official record
Conditions
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
Interventions
cediranib maleate, laboratory biomarker analysis, computed tomography, dynamic contrast-enhanced magnetic resonance imaging, pharmacological study
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 30, 2016 · Synced Sep 5, 2026, 5:42 PM EDT
Completed Phase 2 Interventional Results available

Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma

NCT04493203
View directory record Official record
Conditions
Advanced Melanoma, Unresectable Melanoma
Interventions
Nivolumab, Axitinib
Drug
Lead sponsor
Yana Najjar
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Sep 5, 2026, 5:42 PM EDT
Withdrawn No phase listed Observational

Mitochondrial Dysfunction Contributes to Sepsis Induced Cardiac Dysfunction

NCT05148117
View directory record Official record
Conditions
Sepsis
Interventions
Suspected Sepsis Group - Diagnostic Measurements, Control Group - Diagnostic Measurements
Diagnostic Test
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 5, 2026, 5:42 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia

NCT00233454
View directory record Official record
Conditions
Systemic Mastocytosis, Aggressive (ASM), Leukemia, Mast Cell, Hematological Non-mast Cell Lineage Disease (AHNMD)
Interventions
Midostaurin
Drug
Lead sponsor
Jason Robert Gotlib
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
3
States / cities
Stanford, California • Boston, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Sep 5, 2026, 5:42 PM EDT
Withdrawn Phase 1Phase 2 Interventional

The Transendocardial Autologous Cells (hMSC) or (hMSC) and (hCSC) in Ischemic Heart Failure Trial.

NCT02503280
View directory record Official record
Conditions
Chronic Ischemic Left Ventricular Dysfunction, Myocardial Infarction
Interventions
Autologous hMSCs, Autologous Human C-Kit CSCs II, Placebo, Biosense Webster MyoStar NOGA Injection Catheter System
Drug · Device
Lead sponsor
Joshua M Hare
Other
Eligibility
21 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 5, 2026, 5:42 PM EDT
Completed Phase 2 Interventional Results available

Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure

NCT02501811
View directory record Official record
Conditions
Ischemic Cardiomyopathy
Interventions
Mesenchymal Stem Cells (MSC), c-kit+ cells, Placebo (Plasmalyte A)
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
21 Years to 79 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
7
States / cities
Stanford, California • Gainesville, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2021 · Synced Sep 5, 2026, 5:42 PM EDT
Completed No phase listed Observational

Molecular Mechanisms and Diagnosis of Mastocytosis

NCT00336076
View directory record Official record
Conditions
Mastocytosis
Interventions
Collection of blood and bone marrow
Other
Lead sponsor
University of Michigan
Other
Eligibility
Not listed
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 6, 2016 · Synced Sep 5, 2026, 5:42 PM EDT
Completed Phase 2 Interventional

Imatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer

NCT00248482
View directory record Official record
Conditions
Lung Cancer
Interventions
Cisplatin, Gleevec™, irinotecan
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
2
States / cities
Ann Arbor, Michigan • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 28, 2013 · Synced Sep 5, 2026, 5:42 PM EDT
Completed Phase 1 Interventional

Cardiac Stem Cell Infusion in Patients With Ischemic CardiOmyopathy (SCIPIO)

NCT00474461
View directory record Official record
Conditions
Coronary Artery Disease, Congestive Heart Failure
Interventions
Treatment group
Biological
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Sep 5, 2026, 5:42 PM EDT
Recruiting Phase 1 Interventional

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

NCT06805825
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors, Small-cell Lung Cancer, Adenoid Cystic Carcinoma, Uveal Melanoma, Neuroendocrine Tumors, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
Interventions
NN3201
Drug
Lead sponsor
Novelty Nobility, Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Ann Arbor, Michigan • Cleveland, Ohio • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Sep 5, 2026, 5:42 PM EDT
Completed Phase 2 Interventional Results available

Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy

NCT00509093
View directory record Official record
Conditions
Leukemia
Interventions
imatinib mesylate, gene expression analysis, mutation analysis, polymerase chain reaction, flow cytometry, biopsy
Drug · Genetic · Other + 1 more
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
4
States / cities
Buffalo, New York • Durham, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 16, 2020 · Synced Sep 5, 2026, 5:42 PM EDT
Completed Phase 2 Interventional

Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLC

NCT00156286
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Gleevec
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 15, 2010 · Synced Sep 5, 2026, 5:42 PM EDT
Recruiting Phase 2 Interventional

Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus

NCT05969496
View directory record Official record
Conditions
Renal Cancer, Kidney Cancer, Renal Cell Carcinoma, Inferior Vena Cava Thrombosis
Interventions
Axitinib, Pembrolizumab
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
3
States / cities
Aurora, Colorado • Highlands Ranch, Colorado • Lone Tree, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 5, 2026, 5:42 PM EDT
Completed Phase 1 Interventional

A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors

NCT00619424
View directory record Official record
Conditions
Lung Cancer, Non-Small Cell
Interventions
pazopanib, erlotinib, pemetrexed
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
Aurora, Colorado • Buffalo, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Sep 5, 2026, 5:42 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia

NCT05357482
View directory record Official record
Conditions
Sickle Cell Anemia, Beta Thalassemia
Interventions
TBI, Hydroxyurea, briquilimab, Filgrastim (G-CSF), Sirolimus, Alemtuzumab, Plerixafor
Radiation · Drug · Biological
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
4 Years to 100 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 5, 2026, 5:42 PM EDT
Completed Phase 3 Interventional

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis

NCT00814073
View directory record Official record
Conditions
Indolent Systemic Mastocytosis
Interventions
Masitinib, Placebo, Best Supportive Care
Drug · Other
Lead sponsor
AB Science
Industry
Eligibility
18 Years to 75 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
2
States / cities
Sacramento, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Sep 5, 2026, 5:42 PM EDT
Completed Phase 1 Interventional

Ipilimumab and Imatinib Mesylate in Advanced Cancer

NCT01738139
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, C-KIT Tyrosine Kinase Protein Overexpression, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Gastrointestinal Stromal Tumor, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Melanoma, Unresectable Solid Neoplasm
Interventions
Imatinib Mesylate, Ipilimumab
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Sep 5, 2026, 5:42 PM EDT
Completed Phase 2 Interventional Results available

Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer

NCT00367679
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Lung Cancer, Non-Small Cell
Interventions
Pazopanib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
21 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
10
States / cities
Duarte, California • Rancho Mirage, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2012 · Synced Sep 5, 2026, 5:42 PM EDT
Completed Phase 1 Interventional Results available

The CHILD Trial: Hypoplastic Left Heart Syndrome Study.

NCT03406884
View directory record Official record
Conditions
Hypoplastic Left Heart Syndrome
Interventions
c-kit+ cells
Biological
Lead sponsor
Joshua M Hare
Other
Eligibility
1 Day to 21 Days
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
4
States / cities
Atlanta, Georgia • Chicago, Illinois • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 5, 2026, 5:42 PM EDT
Completed Not applicable Interventional

Evaluation of HepCure Toolkit to Improve Harvoni Adherence

NCT02740556
View directory record Official record
Conditions
Hepatitis C, Medication Adherence
Interventions
HepCure ToolKit, AdhereTech Active Features, AdhereTech Passive Monitoring
Other · Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years to 89 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 22, 2020 · Synced Sep 5, 2026, 5:42 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia

NCT00782067
View directory record Official record
Conditions
Leukemia
Interventions
Midostaurin (PKC412)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
9
States / cities
Los Angeles, California • Stanford, California • Augusta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Sep 5, 2026, 5:42 PM EDT